Myomics

by Phantomics  · Based in South Korea → — Advanced AI Diagnosis for Every Hospital
Cardiology Radiology

Not disclosed
Regulatory Status Disclosed

Overview

Myomics, developed by Phantomics, is an AI-powered software application designed to automate the analysis of cardiac magnetic resonance imaging (MRI) scans. The tool serves as a non-invasive diagnostic support system, providing automated contour detection, quantitative measurements, and tissue characterization to assist in evaluating myocardial diseases.

The platform is built for cardiologists, radiologists, and imaging technicians working in hospital and private practice environments. It integrates into existing clinical workflows by processing standard DICOM format images. By automating labor-intensive manual processes, the software assists clinicians in generating structured reports directly from cardiac imaging data.

Key capabilities of Myomics include:

  • Cardiac Function Analysis: Automated segmentation and calculation of ejection fraction, stroke volume, myocardial mass, and wall motion.
  • T1/T2 Mapping: Native T1, post-contrast T1, and T2 map generation, alongside extracellular volume (ECV) map generation and synthetic hematocrit estimation.
  • Tissue Characterization: Automated quantification of Late Gadolinium Enhancement (LGE) using multiple standard techniques.
  • Strain Analysis: Feature-tracking based strain analysis to assess myocardial deformation.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-based automated contour detection
  • Quick ejection fraction, stroke volume, and mass calculation
  • Wall motion analysis
  • Strain analysis based on feature-tracking
  • T1/T2 mapping (Native T1, Post T1, T2 map generation, synthetic hematocrit estimation, ECV map generation, global and regional analysis, standardized value in Z-score, intuitive 16 segment polar-map)
  • Tissue characterization (Quantification of LGE, automated application of quantification options, synthetic LGE generation)
  • Flow (AI-based aortic and pulmonary contour detection, flow & velocity assessment)
  • Automated reporting function
  • Reduces cardiac MRI analysis time to under 5 minutes
  • Provides clinical insights and preliminary diagnoses through automated evaluation against reference ranges

Use Cases

  • Early detection and prevention of cardiovascular diseases
  • Diagnosis of heart failure, myocardial infarction, myocarditis, and amyloidosis
  • Automated cardiac MRI analysis
  • Assisting cardiologists and radiologists with analytical tools
  • Supporting research with customized data export
  • Non-invasive diagnostic solutions for myocardial diseases

What Physicians Need to Know

Cardiac CT/MRI Analysis
Myomics is an AI-powered solution primarily focused on cardiac MRI analysis, capable of extracting dozens of image biomarkers non-invasively for the diagnosis of myocardial diseases such as heart failure, myocarditis, and amyloidosis. It significantly reduces cardiac MRI analysis time from 20-30 minutes to under 5 minutes while maintaining high diagnostic accuracy. Key features include AI-based automated contour detection, quick ejection fraction, stroke volume, and mass calculation, wall motion analysis, strain analysis based on feature-tracking, T1/T2 mapping (generating native T1, Post T1, T2 maps, synthetic hematocrit estimation, and ECV maps), and quantification of Late Gadolinium Enhancement (LGE). The technology also provides rapid and accurate diagnostic results through medical images such as CT.
Heart Failure Diagnosis Support
The tool aids in the safe and accurate diagnosis of myocardial diseases, including heart failure, by analyzing cardiac MRI images and extracting relevant biomarkers. It offers clinical insights and preliminary diagnoses through automated evaluation of measured values against reference ranges.
Coronary Artery Assessment (via CT/MRI)
Myomics leverages image biomarker technology to provide diagnostic results through medical images like MRI or CT, which can be utilized in the broader assessment of cardiovascular conditions. While not explicitly detailing dedicated coronary artery plaque analysis features, its capability to process cardiac CT and MRI data suggests its potential role in comprehensive cardiovascular imaging workflows.
Regulatory Clearance
Myomics has received FDA 510(k) clearance from the U.S. Food and Drug Administration for its enhanced AI-based cardiac MRI analysis solution, validating its AI-powered analytical capabilities, quality, and safety. It also has regulatory clearance in South Korea, Taiwan, Thailand, and Malaysia.
ECG/EKG Analysis Capability
No information found regarding direct ECG/EKG analysis capabilities for Myomics.
Echocardiography AI Features
No information found regarding specific echocardiography AI features for Myomics.
Arrhythmia Detection Accuracy
No information found regarding arrhythmia detection capabilities or accuracy for Myomics.
Heart Failure Risk Prediction
While Myomics diagnoses heart failure, the search results do not explicitly detail a dedicated 'risk prediction' feature for heart failure beyond its diagnostic capabilities.
Cardiac Monitoring Integration
No information found regarding integration with cardiac monitoring devices for Myomics.
AHA/ACC Guideline Alignment
The search results do not explicitly state Myomics' alignment with AHA/ACC guidelines, though its FDA clearance implies adherence to clinical standards.
Real-Time Alert Capability
No information found regarding real-time alert capabilities for Myomics.
Physician Tip

Myomics offers a significant advantage in streamlining cardiac MRI analysis, reducing interpretation time from 20-30 minutes to under 5 minutes, which can greatly enhance workflow efficiency in busy cardiology departments. Its AI-driven automated segmentation and quantitative biomarker extraction provide precise visualization and localization, aiding in the accurate diagnosis of complex myocardial diseases like heart failure, myocarditis, and amyloidosis. Physicians can leverage its detailed functional and tissue characterization capabilities, including ejection fraction, strain analysis, and T1/T2 mapping, to gain deeper insights into cardiac health and pathology. The FDA clearance further supports its reliability for clinical use.

Phantomics, the developer of Myomics, is actively seeking partnerships with platform vendors specializing in medical imaging (MRI, CT, X-ray, ultrasound) to integrate Myomics into existing hospital platforms. This suggests a focus on interoperability to allow seamless incorporation into diverse healthcare IT ecosystems, potentially facilitating data access and utilization within broader clinical workflows.

Details

Category Cardiology AI, Radiology & Imaging AI
Pricing Not disclosed — Contact for pricing
DeploymentIntegrated into PACS systems; deployed in hospitals
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

Myomics received U.S. FDA 510(k) clearance (K241922) on February 28, 2025. It is intended for viewing, post-processing, qualitative and quantitative evaluation of cardiovascular magnetic resonance (MR) images in DICOM format. It provides tools to assist physicians in assessing cardiac images, performing quantitative measurements of the heart and adjacent vessels, and viewing physician-identified lesions in blood vessels.

Integrations
EHR Not specified
Specialties Cardiology, Radiology

What the Web Says

Myomics is an AI-powered platform that offers multi-omics data analysis and visualization, with a particular focus on cardiac MRI analysis. It aims to provide a unified, secure, and privacy-first platform for integrated genomic, epigenomic, and metabolic profiling with clinical interpretation. The company, Phantomics, recently received FDA 510(k) clearance for its enhanced AI-based cardiac MRI analysis solution, allowing it to enter the U.S. market. Myomics is also recognized for its ability to significantly reduce cardiac MRI analysis time while maintaining high diagnostic accuracy.

Overall: Positive

Strengths

  • Reduces cardiac MRI analysis time from 20-30 minutes to under 5 minutes.
  • Maintains high diagnostic accuracy for cardiac conditions.
  • Offers a unified platform for multi-omics data analysis, including genetics, epigenetics, and microbiome.
  • Provides an easy-to-use solution for exploring omics data based on the Galaxy framework.
  • Utilizes AI and machine learning for personalized clinical diagnosis and improved diagnostic accuracy.
  • FDA 510(k) clearance validates its AI-powered analytical capabilities, quality, and safety.

Limitations

  • Some features may be for research use only and not available for clinical use in certain regions.
  • General concerns exist regarding the accuracy and trustworthiness of AI tools for diagnostic purposes, as they are still in development and can have a high margin of error.
  • No specific negative reviews or opinions from physicians, healthcare IT, tech reviewers, Reddit, G2, or Capterra were found directly addressing Myomics, making it difficult to identify specific cons from these sources.
  • The platform's comprehensive capabilities might require time for users to fully utilize.

Based on reviews from: SPIE Digital Library, Myomics (myomics.com), PMC (PubMed Central), p4 Medicine Smart Solutions, Phantomics, YouTube

Last updated: 2026-07-18

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Myomics

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Phantomics News
Phantomics Secures FDA 510(k) Clearance for Enhanced AI-Powered Cardiac MRI Solution 'Myomics'
Phantomics announced FDA 510(k) clearance for an enhanced version of its AI-based cardiac MRI analysis solution, Myomics, enabling its entry into the U.S. cardiovascular disease diagnostics market. The solution reduces cardiac MRI analysis time from 20-30 minutes to under 5 minutes while maintaining high diagnostic accuracy.
2025-03
AVING NEWS
Phantomics Introduces 'Myomics' Equipped with Non-Invasive Heart MRI Image Analysis Technology at CES 2024u2026 u201cWinning Innovation Award with AI Diagnostic Technology!u201d
Phantomics showcased its medical AI solution 'Myomics' at CES 2024, where it received an Innovation Award in the digital healthcare sector. Myomics utilizes cardiac MRI to non-invasively extract image biomarkers for diagnosing myocardial diseases like heart failure and myocarditis.
2024-01
myOMICS (myomics.com)
Digital technological innovation in personalized precision medicine - myOMICS
This project focuses on providing technological support for personalized precision medicine by developing digital 4.0 technologies and tools to collect and integrate large databases of multi-omics data. The goal is to understand relationships between biomolecules and regulatory mechanisms to boost clinical healthcare.
2025-06
myOMICS -p4 Medicine Smart Solutions
About Us u2013 myOMICS -p4 Medicine Smart Solutions
myOMICS -p4 Medicine Smart Solutions, founded in June 2020, aims to transform healthcare towards personalized precision medicine by integrating biodata from multi-omics technologies into clinical practice. They offer R&D consulting and management, with expertise in evaluating health units and managing scientific projects.
2020-06
Phantomics
Myomics - Phantomics
Myomics is an AI-powered cardiac MRI and CT solution that automates cardiac function analysis and report generation, with regulatory clearance in multiple countries including the U.S. It aims to eliminate labor-intensive manual processes and provide precise visualization for diagnosis.
unknown
Frontiers in Cardiovascular Medicine
From multi-omics approaches to personalized medicine in myocardial infarction - Frontiers
This review article discusses the application of multi-omics approaches, including genomics, transcriptomics, proteomics, and metabolomics, in understanding myocardial infarction (MI) and advancing personalized medicine. It highlights how these integrated approaches can overcome the limitations of single-omics studies to improve diagnosis, treatment, and prognosis of MI.
2023-10
International Journal of Medical Science and Clinical Research Studies
Multi-Omics Integration in Personalized Medicine: Advancing Laboratory Diagnostics and Precision Therapeutics in the Era of Individualized Healthcare
This review explores the role of personalized medicine in laboratory diagnostics and patient management through emerging omics technologies. It emphasizes that integrating multi-omics data can lead to more accurate diagnoses, targeted therapies, and improved treatment outcomes, particularly in complex diseases.
2025-05
International Journal of Medical Science and Clinical Research Studies
Clinical Applications of Multi-Omics Integration in Disease Diagnosis
This article highlights the growing value of multi-omics integration in clinical settings for improving diagnostic accuracy, enabling earlier disease detection, and refining patient stratification. It discusses how combining genomic, transcriptomic, proteomic, metabolomic, and epigenomic data offers a comprehensive view of disease biology.
2026-01

Videos

Product demos, reviews, and walkthroughs for Myomics.

View all on YouTube

Frequently Asked Questions

Myomics is designed to seamlessly integrate with existing cardiac MRI systems, automating image analysis and report generation. It significantly reduces analysis time from 20-30 minutes to under 5 minutes, improving diagnostic efficiency for conditions like heart failure, myocarditis, and amyloidosis.
Myomics has received FDA 510(k) clearance in the U.S., along with approvals in South Korea, Taiwan, Thailand, and Malaysia, validating its safety and performance. While specific data privacy protocols are not detailed in the provided information, medical AI solutions typically adhere to stringent healthcare data protection regulations.
While Myomics aims for high diagnostic accuracy, like all AI, it may have limitations in atypical or rare cases not well-represented in its training data. Physicians should use Myomics as a decision support tool, integrating its insights with their clinical judgment and other patient data, especially for complex diagnoses.
Myomics significantly enhances efficiency by automating cardiac MRI analysis, reducing manual interpretation time from 20-30 minutes to under 5 minutes, while maintaining high diagnostic accuracy. This automation helps evaluate heart performance and detect structural problems more rapidly and consistently than traditional manual methods.
The provided search results do not detail the specific pricing structure for Myomics. Typically, healthcare AI solutions like Myomics are offered through licensing agreements, subscription models, or per-study fees, with costs potentially varying based on hospital size, usage volume, and required integration services.
Phantomics emphasizes ease of use and provides an optimized explanation function for doctors, nurses, and patients, along with a workflow that integrates into hospital information systems. While specific training programs are not detailed, the company likely offers comprehensive onboarding and ongoing technical support to ensure effective utilization within clinical workflows.

Related Tools

EchoMD AutoEF
Caption Health (formerly Bay Labs, now part of GE HealthCare)
Cardiology AI
EchoMD AutoEF is an FDA-cleared AI software that automates the selection of echocardiogram clips and calculates left ventricular ejection fraction (EF), enhancing efficiency and accuracy in cardiac assessments.
ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm
Anumana, Inc.
Cardiology AI
An AI algorithm for screening cardiac amyloidosis using standard 12-lead ECGs.
DEEPVESSEL Plaque
Keya Medical Technology Co., Ltd.
Cardiology AI
An AI software platform for coronary plaque analysis and quantification from CT angiography.
WatchMate Software
Anumana, Inc.
Cardiology AI
Anumana is an AI-driven health technology company from nference, developing and delivering ECG algorithms enabling early diagnosis and intervention.
syngo.CT Coronary Cockpit
Siemens Healthineers
Cardiology AI
syngo.CT Coronary Cockpit is an AI-powered software tool by Siemens Healthineers for efficient and accurate CT coronary angiography analysis.
HeartLung AI-CVD®
HeartLung Corporation
Cardiology AI
HeartLung AI-CVD® is an FDA-cleared AI-powered quantitative imaging tool that provides automated CT-derived measurements for assessing cardiovascular and multisystem risks opportunistically.

See all Cardiology AI tools →

Suggest an Edit → | Last Verified: 2026-04-19 | First Added: 2026-04-19
AI Tool Finder
AI-powered search. Results may not be comprehensive.